These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 38790090

  • 21. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.
    Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M.
    World J Gastroenterol; 2017 Jan 28; 23(4):668-675. PubMed ID: 28216974
    [Abstract] [Full Text] [Related]

  • 22. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG, Jiang X, Ding YB, She Q, Li YY.
    Helicobacter; 2024 Jan 28; 29(1):e13040. PubMed ID: 37983865
    [Abstract] [Full Text] [Related]

  • 23. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS, Kim EH, Park CH.
    Aliment Pharmacol Ther; 2017 Jul 28; 46(2):106-114. PubMed ID: 28497487
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL, Lin BS, Li YY, Ding YM, Han ZX, Ji R.
    Digestion; 2023 Jul 28; 104(4):249-261. PubMed ID: 37015201
    [Abstract] [Full Text] [Related]

  • 25. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
    Feng JH, Cheng J, Lao YJ, Huang K, Mou JL, Hu F, Lin ML, Lin J.
    Eur J Med Res; 2023 Aug 07; 28(1):272. PubMed ID: 37550781
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T.
    Dig Dis Sci; 2017 Nov 07; 62(11):3069-3076. PubMed ID: 28664410
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
    Kanu JE, Soldera J.
    World J Gastroenterol; 2024 Mar 07; 30(9):1213-1223. PubMed ID: 38577188
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.
    Gao W, Wang Q, Zhang X, Wang L.
    Int J Immunopathol Pharmacol; 2024 Mar 07; 38():3946320241286866. PubMed ID: 39305222
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
    Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, Ikehara H, Gotoda T.
    J Gastroenterol Hepatol; 2021 Dec 07; 36(12):3314-3321. PubMed ID: 34107551
    [Abstract] [Full Text] [Related]

  • 36. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 37. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
    Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ.
    World J Gastroenterol; 2014 Oct 28; 20(40):14973-85. PubMed ID: 25356059
    [Abstract] [Full Text] [Related]

  • 38. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J, Li YY, Lin MJ, Liu J, Lin BS, Ding YM, Wan M, Zhang WL, Kong QZ, Wang ST, Mu YJ, Duan M, Han ZX, Zuo XL, Li YQ.
    J Dig Dis; 2023 Jan 28; 24(1):19-27. PubMed ID: 36960538
    [Abstract] [Full Text] [Related]

  • 39. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Hu Y, Huang XH, Zhou B, Liu ML, Liu YF, Yu T, Sun P, Tan BB, Hu Y, Cheng F, Pan XL, Hong JB, Shu X, Zhu Y, Lu NH.
    Helicobacter; 2024 Jan 28; 29(1):e13045. PubMed ID: 39191423
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.